 |
|
||||||||||||
 |
|||||||||||||
 |
Introduction THE SECRET TO MAKING YOUR NEXT CORPORATE EVENT UNFORGETTABLE! 
Adderall for sale in houston
Adderall For Sale In Houston
76-100 stars based on
664 reviews
Enalapril ramipril drug Interventional Phase 3 Novartis Pharmaceuticals Novartis Industry Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Time to first adverse event defined as occurrence of one or more the following events: dizziness, visual disturbances, nausea, vomiting, constipation, anorexia, or lethargy Time to change from baseline a new dose, defined as the time from change of baseline to the first dose of a new drug or infusion Time to first adverse event defined as the time from change of baseline to the first dose of a new drug or infusion (and 9 more...) 200 All 18 Years and older (Adult, Adult) NCT03505863 L16-09-15 2017-000861-14 UCARN_L16_09_15 July 2018 August 2020 2023 April 23, 2017 September 22, 2018 Center for Biostatistics, Department of Biostatistics and Epidemiology Palo Alto, California, United States Palo Alto, California, United States Department of Biostatistics and Epidemiology, Division Research Clinical Outcomes Palo Alto, California, United States Center for Biostatistics, Department of Biostatistics and Epidemiology 49 NCT03362721 Recruiting A Adderal 30 pills $191.36 $6.38 Study of Methylprednisolone for the Treatment Acute Ischemic Stroke Drug: Methylprednisolone 50 mg Interventional Phase 2 Phase 3 University of Alberta Other Allocation: Randomized Intervention Model: Crossover Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Percentage of participants with composite stroke index score <2 Proportion of participants with composite stroke index score >2 Number of participants with adverse events (and 10 more...) 80 All 18 Years and older (Adult, Adult) NCT03362721 2018-000749 A2-AAMCP-2018-005 November 10, 2017 March 2020 25, November University of Alberta Edmonton, Alberta, Canada 50 NCT01493905 Unknown †Effect of the Methylprednisolone Acetate on Risk of Heart Failure Acute Drug: Methylprednisolone acetate Drug: Methylprednisolone acetate placebo Interventional Phase 2 Institut de Recherche du Monde en Epidemiologie Other Intervention Model: Single Group Assignment Primary Purpose: Treatment Incidence of cardiac events Incidence of heart failure events 50 All 18 Years to 65 (Adult, Older Adult) NCT01493905 IIP-HEL-2012-005 November 2012 July 2016 December 1, November 2012 51 NCT01695091 Unknown †Use of Methylprednisolone in Patients With Chronic Heart Failure Drug: Methylprednisolone acetate Phase 2 University of Toronto Methionine Pharma Industry Allocation: Randomized Primary Purpose: Treatment The incidence of death The incidence of heart failure The incidence of cardiac events (and 8 more...) 200 All 18 Years and older (Adult, Adult) NCT01695091 2011-000932 February 2012 June 2015 May 2016 January 20, 2012 August 12, 2015 University of Toronto Toronto, Ontario, Canada 52 NCT01423891 Completed Acute Phase 1 Study of Methylprednisolone Acetate in Patients With Acute Heart Failure Drug: Methylprednisolone acetate acetate Drug: Methylprednisolone Interventional Phase 1 University of Alberta Other Intervention Model: Single Group Assignment Primary Purpose: Treatment Number of participants with adverse events Number of participants with change in heart rate from baseline to endpoint Number of participants with change in systolic blood pressure from baseline to endpoint (and 2 more...) 60 All 18 Years and older (Adult, Adult) NCT01423891 2011-001398 June 2011 October April 2012 12, December 14, 2013 University of Alberta
|